Medoxicam (Meloxicam)

Meloxicam selectively blocks the cyclooxygenase‑2 (COX‑2) enzyme, which is responsible for producing prostaglandins that mediate inflammation, pain, and fever. By inhibiting COX‑2, meloxicam lowers prostaglandin levels, thereby decreasing inflammatory responses while sparing COX‑1 activity that protects the stomach lining.

The appropriate dose of Medoxicam is determined by the prescribing healthcare professional based on the patient’s condition, severity, age, renal and hepatic function, and other individual factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of meloxicam in pregnancy has not been established, and it is generally avoided unless the potential benefit outweighs the risk. Limited data are available for breastfeeding, and caution is advised because the drug may be excreted in milk. Consultation with a healthcare provider is essential before use.

To request Medoxicam, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with non‑selective NSAIDs, meloxicam offers greater COX‑2 selectivity, which may reduce the risk of gastrointestinal irritation while still providing effective anti‑inflammatory and analgesic action. However, cardiovascular and renal risks remain similar to other NSAIDs, so patient‑specific factors guide drug choice.

Medoxicam should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat, and direct sunlight to maintain its stability and potency throughout its shelf life.

Medoxicam is taken orally, usually as a tablet, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water and follow the dosing schedule provided by the healthcare professional.

Serious risks include gastrointestinal bleeding or ulceration, cardiovascular events such as heart attack or stroke, severe skin reactions (e.g., Stevens‑Johnson syndrome), liver injury, and renal impairment. Patients should be monitored for signs of these conditions and seek immediate medical attention if they occur.

Medoxicam is contraindicated in individuals with known hypersensitivity to meloxicam, other oxicams, or any NSAID, as well as in patients with active gastrointestinal ulceration or bleeding, severe heart failure, and those who have had a recent coronary artery bypass graft. It should also be used with caution in the elderly and in patients with compromised renal or hepatic function.